Litton Mark James 4

What Happened

• Mark James Litton, President, CEO and Director of LeonaBio, was granted a derivative award on 2026-04-09 covering 750,000 shares. The Form 4 reports an acquisition value of $0.00 for the award (transaction code A), indicating a grant of option(s) rather than an open-market purchase or sale. This is a compensation grant, not an immediate purchase or sale of vested shares.

Key Details

• Transaction date and price: 2026-04-09; reported acquisition price $0.00 (award/option).
• Vesting: The award vests monthly over 48 months (monthly anniversaries of the grant), subject to continued service under the issuer's 2026 Equity Incentive Plan (see footnote).
• Shares owned after transaction: Not specified in the provided Form 4.
• Filing timeliness: Reported on 2026-04-13 — filed within the two-business-day Form 4 deadline, so the filing appears timely.
• Footnote: The filing states the shares are subject to an option that vests monthly over 48 months while the grantee remains a “Service Provider.”

Context

• This was an option grant (derivative award), not an exercise or cash purchase — no new vested shares were transferred to Litton at grant and no immediate sale occurred. Such grants are normally part of executive compensation and do not necessarily indicate near-term buying or selling activity by the insider. If Litton later vests and exercises or sells shares, additional Form 4s would be filed.